Clinical trials ongoing
ADIPOSE CELL DERIVED REGENRATIVE ENDOTHELIAL ANGIOGENIC MEDICINE (ACELLDREAM2)
The main purpose of this study is to evaluate the efficacy of regenerative therapy with expanded adipose derived stromal/stem cells, administered intramuscularly in patients with critical leg ischemia.
|
Clinical indication Critical limb ischemia |
Disease area Cardiology/Vascular |
Cell type ASC |
Autologous/allogeneic Autologous |
|
Route of administration Intramuscular |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase Phase 2 |
Recruitment target 43 |
Year trial started 2019 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Alessandra Bura-Rivière (Toulouse University hospital, France)
ECELLFrance activity : Cell production (ATMP) (Créteil)
ECELLFrance contact : Hélène Rouard
Efficacy in Alveolar Bone Regeneration With Autologous MSCs and Biomaterial in Comparison to Autologous Bone Grafting (Maxibone)
A randomized controlled clinical multi center trial to assess the efficacy of a combination of autologous mesenchymal stem cells and biomaterial in jaw bone regeneration prior to dental implant placement in comparison to standard autologous bone block grafting.
|
Clinical indication Alveolar bone atrophy |
Disease area Muskeletal |
Cell type BM-MSC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial Yes |
Transgene No |
Activation/differentiation No |
|
Trial phase Phase 3 |
Recruitment target 150 |
Year trial started 2019 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Kamal Mustafa (University Hospital of Southern Denmark)
ECELLFrance activity : Cell production (ATMP) (Créteil)
ECELLFrance contact : Hélène Rouard
Systemic injection of HLA mesenchymal stem cells from intra-familial donor for the treatment of Recessive Dystrophic Epidermolysis Bullosa (MESEBDR)
Phase 1/2 pilot clinical trial, to evaluate the safety and preliminary efficacy of the systemic infusion of mesenchymal stem cells derived from bone marrow (BM-MSCs) from a haploidentical donor to improve the healing process and / or the mucocutaneous fragility phenotype associated with recessive dystrophic epidermolysis bullosa .
|
Clinical indication Epidermolysis Bullosa |
Disease area Dermatology |
Cell type BM-MSC |
Autologous/allogeneic Autologous |
|
Route of administration Systemic |
Biomaterial Yes |
Transgene No |
Activation/differentiation No |
|
Trial phase 1/2 |
Recruitment target 9 |
Year trial started 2018 |
Trial status Active, not recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Instituto de Investigación Hospital Universitario La Paz
EcellFrance activity : Cell production (ATMP) (Clamart)
ECELLFrance contact : Christophe Martinaud
REgenerative therapy of intervertebral disc (RESPINE)
A double blind phase 2b trial of intradiscal injection of bone marrow derived mesenchymal stromal cells in degenerative disc disease unresponsive to conventional therapy
|
Clinical indication Disc Degenerative Disease |
Disease area Musculoskeletal |
Cell type BM-MSC |
Autologous/allogeneic Allogeneic |
|
Route of administration Local |
Biomaterial Yes |
Transgene No |
Activation/differentiation No |
|
Trial phase 2b |
Recruitment target 112 |
Year trial started 2018 |
Trial status Recruiting |
|
Clinical trial ID |
Website |
Principal investigator : Christian Jorgensen (ECELLFrance)
ECELLFrance activity : Biodistribution (Toulouse), immunomonitoring (Montpellier, Rennes), regulatory dossier, coordination (Christian Jorgensen)
ECELLFrance contact : Christian Jorgensen
Regenerative Stem Cell Therapy for Stroke in Europe (RESSTORE)
The study purpose is to explore the efficacy (functional recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells (ADSC) in 400 stroke patients. Therapeutic effects of ADSCs will be assessed and monitored in patients using clinical rating scales, multimodal MRI and blood biomarkers.
|
Clinical indication Stroke |
Disease area Neurology |
Cell type ASC |
Autologous/allogeneic Allogeneic |
|
Route of administration Systemic |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase IIb |
Recruitment target 400 (200 treated) |
Year trial started 2016 |
Trial status Recruiting |
|
Clinical trial ID |
Website |
Principal investigator: Olivier Detante (ECELLFrance)
ECELLFrance activities : Cell production (ATMP) (Grenoble, Créteil, Clamart), cell potency/QC and biodistribution (Toulouse), patient immunomonitoring (Rennes, Montpellier), coordination (Olivier Detante)
ECELLFrance contact : Olivier Detante
Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy (PRISME)
The aim of the study is to evaluate the efficacy of systemic mesenchymal stromal cell (MSC) injections for the treatment of severe and chronic radiotherapy-induced abdomino-pelvic complications
|
Clinical indication Pelvic radiation disease |
Disease area Dermatology |
Cell type BMSC |
Autologous/allogeneic Allogeneic |
|
Route of administration Systemic |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 2 |
Recruitment target 12 |
Year trial started 2016 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Mohamad MOHTY (APHP, France)
ECELLFrance activity : Cell production (ATMP), cell potency/QC (Toulouse), patient immunomonitoring (Rennes, Montpellier), coordination (Jean-Jacques Lataillade)
ECELLFrance contact : Christophe Martinaud
ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft in long bone nonUNIONs (ORTHOUNION)
This clinical trial involves two comparative analyses :
- Comparison of efficacy in terms of superiority of hBM-MSCs + biomaterial (both experimental arms, low and high doses) versus iliac crest autologous graft (active comparator arm).
- Comparison of efficacy in terms of non-inferiority of low dose hBM-MSC+biomaterial versus high dose of hBM-MSC+biomaterial.
|
Clinical indication Long bone nonUNIONs |
Disease area Musculoskeletal |
Cell type BM-MSC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial Yes |
Transgene No |
Activation/differentiation No |
|
Trial phase 3 |
Recruitment target 108 |
Year trial started 2014 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Enrique Gomez-Barrena (Universidad Autonoma de Madrid)
ECELLFrance activities : Cell production (ATMP) (Toulouse, Créteil), gene modification/transfection (Toulouse), cell potency/QC (Toulouse), patient immunomonitoring (Rennes, Montpellier), coordination (Luc Sensebé)
ECELLFrance contact : Hélène Rouard
Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis. (ADIPOA2)
The objective of the study is to conduct a prospective, multicenter single blinded, placebo controlled Phase II study, comparing culture-expanded, autologous adult adipose-MSCs in subjects with knee osteoarthritis unresponsive to conservative therapy for at least 12 months.
|
Clinical indication Osteoarthritis |
Disease area Musculoskeletal |
Cell type ASC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 2b |
Recruitment target 150 |
Year trial started 2016 |
Trial status Recruiting |
|
Clinical trial ID |
Website |
Principal investigator : Christian Jorgensen (ECELLFrance)
ECELLFrance activities : Cell production (ATMP) (Toulouse, Créteil), cell potency/QC (Toulouse), patient immunomonitoring (Rennes, Montpellier)
ECELLFrance contact : Christian Jorgensen
Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)
Investigators initiated the MESAMI program by the bicentric pilot phase and highlighted the safety and feasibility of intramyocardial injections of MSCs from bone marrow in patients with chronic ischemic cardiomyopathy and left ventricular dysfunction, guided by the NOGA-XP system. The MESAMI program continues with the phase 2, multicenter, double-blind, randomized, placebo-controlled trial. The aim of this phase 2 study is to demonstrate a functional improvement, measuring peak VO2, at 3 months between the cell therapy group and the placebo group.
|
Clinical indication Chronic Myocardial Ischemia |
Disease area Cardiology/Vascular |
Cell type BMSC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 2 |
Recruitment target 80 (45 treated) |
Year trial started 2016 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Jérome Roncalli (Toulouse University hospital, France)
ECELLFrance activity : Cell production (ATMP)
ECELLFrance contact : Hélène Rouard
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells (MSC)
The main ailm of this phase I-II study is to evaluate toxicity and efficacy of allogenic mesenchymal stem cell therapy to treat severe systemic sclerosis. In practice this treatment will be given to patients with a rapidly evolutive disease or refractory to cyclophosphamide
|
Clinical indication Scleroderma |
Disease area Immunology |
Cell type BMSC |
Autologous/allogeneic Allogeneic |
|
Route of administration Systemic |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 2b |
Recruitment target 20 |
Year trial started 2014 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Dominique Farges (AP-HP), France
ECELLFrance activities : cell production (ATMP), patient immunomonitoring
ECELLFrance contact : Christian Jorgensen
Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip (ORTHO-2)
The aim of the study is to assess the safety and feasibility of an in situ single injection of a high dose of autologous bone marrow-derived, in vitro expanded Mesenchymal stem cells, and its contribution to the resolution of the early stages of avascular osteonecrosis of the femoral head.
|
Clinical indication Avascular Necrosis of the Femoral Head |
Disease area Musculoskeletal |
Cell type BMSC |
Autologous/allogeneic Autologous |
|
Route of administration Local |
Biomaterial No |
Transgene No |
Activation/differentiation No |
|
Trial phase 2 |
Recruitment target 30 |
Year trial started 2014 |
Trial status Recruiting |
|
Clinical trial ID |
Website - |
Principal investigator : Pierre Layrolle (Toulouse University Hospital, France)
ECELLFrance activities : Cell production (ATMP), gene modification/transfection, cell potency/QC, patient immunomonitoring, coordination (Luc Sensebé)
ECELLFrance contact : Hélène Rouard